Director, Clinical Data Management
Korro Bio
About this role
Korro is a biopharmaceutical company developing genetic medicines using its proprietary RNA editing platform. The company focuses on creating precise, transient RNA edits for a range of diseases, aiming to expand treatment options with increased specificity and tolerability.
Skills
About Korro Bio
korrobio.comKorro Bio is a biotechnology company developing precision RNA‑editing therapeutics that edit a single letter on RNA to modulate biological pathways. Their mission is to translate this platform into genetic-medicine solutions for complex, prevalent diseases by advancing a focused therapeutic pipeline. The company emphasizes moving its science toward patient‑facing programs and resources (for example, work relevant to AATD) to deliver targeted, durable treatments.
Recent company news
SahmKorro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
4 days ago
Simply Wall StreetKorro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
4 days ago
BioSpaceJPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Jan 16, 2026
The Globe and MailAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
4 days ago
MSNKorro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates
1 day ago
About Korro Bio
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for Korro Bio.
Salary
$119k – $162k
per year